Latham & Watkins Advises Zentalis Pharmaceuticals in US$200.2 Million Underwritten Offering of Common Stock

Firm represents the clinical-stage biopharmaceutical company in the offering.

May 17, 2022

Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, has announced the pricing of an underwritten offering of 10,330,000 shares of its common stock at an offering price of US$19.38 per share, for total gross proceeds of approximately US$200.2 million, before deducting underwriting discounts and commissions and offering expenses payable by Zentalis. All of the common stock is being offered by Zentalis. The offering is expected to close on May 18, 2022, subject to customary closing conditions.

Latham & Watkins LLP represents Zentalis Pharmaceuticals, Inc. in the offering with a corporate team led by partner Nathan Ajiashvili, with associates Salvatore Vanchieri, Matt DeSilva, and Darby Dietrich. Advice was also provided on public company representation matters led by partner Jenna Cooper, with associates Nicole McNeil and Hamna Ahmad.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.